MBI moves forward with Optison
Contrast agent developer Molecular Biosystems has completed phase II studies for its myocardial perfusion agent, Optison, and has submitted its results to the Food and Drug Administration. The trials consisted of six studies with 376 participants
Contrast agent developer Molecular Biosystems has completed phase II studies for its myocardial perfusion agent, Optison, and has submitted its results to the Food and Drug Administration. The trials consisted of six studies with 376 participants experiencing known or suspected coronary artery disease, and showed that Optison Myocardial Contrast Echocardiography (MCE) tests were comparable to the standard clinical tests, either SPECT or coronary angiography, according to San Diego-based MBI. MBI now plans to proceed to phase III clinical trials for the agent.
Meanwhile, sales of Optison continue outside the U.S. Optison was cleared for sale in Europe in 1998 (SCAN 5/27/98), and is sold there by MBIs marketing partner, St. Louis-based Mallinckrodt. Earlier this year, MBI signed a licensing agreement with Chugai Pharmaceuticals for marketing of the agent in Japan, South Korea, and Taiwan (SCAN 6/9/99).
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
